Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine (CanSino Biologics Inc.)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PCV13 vaccine, specifically the 13-valent pneumococcal polysaccharide conjugate vaccine developed by CanSino Biologics (often designated as PCV13i), is a conjugate vaccine indicated for the prevention of invasive pneumococcal disease caused by *Streptococcus pneumoniae*. It targets 13 common serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The vaccine works by conjugating these bacterial capsular polysaccharides to a carrier protein, CRM197, which enhances the immune response by engaging T-cells, making it effective in infants and young children. CanSino's formulation was designed to optimize the manufacturing process and improve the stability and immunogenicity of the vaccine. It received marketing approval from the China National Medical Products Administration (NMPA) in April 2024 for use in infants and children.
- Brand names
- WeigancaiPrevnar 13Prevnar13Prevnar-13
- Other names
- 13-valent pneumococcal polysaccharide conjugate vaccine13-valent pneumococcal conjugate vaccinePneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)
02
Targets
CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 6BCPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine (CanSino Biologics Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine (CanSino Biologics Inc.).